On May 3, 2023, Aridis Pharmaceuticals, Inc. sent written notice to Serum AMR Products (Serum) stating that as of May 8, 2023, the License, Development and Commercialization Agreement between the Company and Serum would terminate pursuant to Section 13.3(a) of the Agreement for nonfulfillment of development obligations under the Agreement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.057 USD | -5.50% | -5.00% | -18.69% |
1st Jan change | Capi. | |
---|---|---|
-18.69% | 2.73M | |
+8.63% | 114B | |
+13.17% | 107B | |
-12.76% | 22.22B | |
-2.45% | 21.28B | |
-4.97% | 18.8B | |
-7.19% | 17.51B | |
-39.93% | 17.17B | |
+6.67% | 14.14B | |
+33.90% | 12.2B |
- Stock Market
- Equities
- ARDS Stock
- News Aridis Pharmaceuticals, Inc.
- Aridis Pharmaceuticals, Inc. Terminates License, Development and Commercialization Agreement with Serum